HomeCompareIPMLF vs ABBV

IPMLF vs ABBV: Dividend Comparison 2026

IPMLF yields 35.97% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IPMLF wins by $83.4K in total portfolio value
10 years
IPMLF
IPMLF
● Live price
35.97%
Share price
$5.56
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$185.7K
Annual income
$28,708.73
Full IPMLF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — IPMLF vs ABBV

📍 IPMLF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIPMLFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IPMLF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IPMLF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IPMLF
Annual income on $10K today (after 15% tax)
$3,057.55/yr
After 10yr DRIP, annual income (after tax)
$24,402.42/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, IPMLF beats the other by $3,346.42/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IPMLF + ABBV for your $10,000?

IPMLF: 50%ABBV: 50%
100% ABBV50/50100% IPMLF
Portfolio after 10yr
$144.0K
Annual income
$26,740.25/yr
Blended yield
18.57%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

IPMLF
No analyst data
Altman Z
2.1
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IPMLF buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIPMLFABBV
Forward yield35.97%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$185.7K$102.3K
Annual income after 10y$28,708.73$24,771.77
Total dividends collected$135.2K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: IPMLF vs ABBV ($10,000, DRIP)

YearIPMLF PortfolioIPMLF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$14,297$3,597.12$11,550$430.00+$2.7KIPMLF
2$20,104$4,806.40$13,472$627.96+$6.6KIPMLF
3$27,828$6,316.51$15,906$926.08+$11.9KIPMLF
4$37,947$8,171.24$19,071$1,382.55+$18.9KIPMLF
5$51,017$10,413.61$23,302$2,095.81+$27.7KIPMLF
6$67,673$13,084.39$29,150$3,237.93+$38.5KIPMLF
7$88,631$16,220.61$37,536$5,121.41+$51.1KIPMLF
8$114,689$19,854.20$50,079$8,338.38+$64.6KIPMLF
9$146,728$24,010.79$69,753$14,065.80+$77.0KIPMLF
10$185,708$28,708.73$102,337$24,771.77+$83.4KIPMLF

IPMLF vs ABBV: Complete Analysis 2026

IPMLFStock

Imperial Metals Corporation, a mining company, engages in the acquisition, exploration, development, mining, and production of base and precious metals in Canada. It holds 100% interests in the Mount Polley copper-gold mine that includes seven mining leases and 50 mineral claims covering an area of 23,369 hectares located in south-central British Columbia; and the Huckleberry copper mine, which comprises two mining leases and 49 mineral claims covering an area of 25,767 hectares situated in west-central British Columbia. The company also holds a 30% interest in the Red Chris copper-gold mine located in northwest British Columbia. In addition, it holds a 100% interest in the Ruddock Creek lead-zinc property in British Columbia, as well as a portfolio of 23 greenfield exploration properties in British Columbia. Imperial Metals Corporation was incorporated in 1959 and is headquartered in Vancouver, Canada.

Full IPMLF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this IPMLF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IPMLF vs SCHDIPMLF vs JEPIIPMLF vs OIPMLF vs KOIPMLF vs MAINIPMLF vs JNJIPMLF vs MRKIPMLF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.